Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.

Dr. Reddy's launches generic Bosutinib 400mg with 180-day U.S. exclusivity; brand equivalent (Bosulif) had $253.8M annual sales. The first-to-file advantage signals India's complex oncology capability and cost pressure on branded cancer therapies for healthcare portfolios.